The clinical efficacy of nintedanib, a tyrosine kinase inhibitor targeting PDGFR, FGFR, and VEGRF [190], across IPF [191], systemic sclerosis-ILD [192], and progressive fibrosing CTD-ILD [193] underscores the centrality of these interconnected growth-factor pathways in autoimmune-driven lung fibrosis. Here, PDGFRB is linked to interstitial lung disease.